Regeneron Pharmaceuticals (REGN) Earnings Date & Reports

Key Takeaways

• Earnings date confirmed: Regeneron will report second-quarter 2026 results on Thursday, July 30, before the U.S. market opens, followed by a conference call at 8:30 AM Eastern Time.
• Consensus estimates: Analysts expect adjusted earnings per share (EPS) of approximately $10.61 to $10.85 on revenue of roughly $3.82 billion, according to consensus data from multiple sources.
• Dupixent remains the growth engine: The Sanofi-partnered blockbuster generated $4.9 billion in global net sales in Q1 2026, up 33% year-over-year, and its momentum will be a focal point for investors.
• Eylea franchise transition under scrutiny: Eylea HD U.S. net sales grew 52% in Q1, but legacy Eylea sales fell 36%, and the combined franchise declined 10%. The pace of patient conversion remains a critical metric.
• Manufacturing and regulatory updates expected: A temporary Limerick manufacturing interruption is expected to weigh on Q2 GAAP margins, while an FDA decision on the Eylea HD pre-filled syringe could arrive this quarter.
• Stock under pressure: REGN shares have declined roughly 9% since the Q1 2026 report and are trading below their 200-day moving average, adding significance to this earnings release.

Earnings Context and Why It Matters

Regeneron Pharmaceuticals enters its second-quarter 2026 earnings report at a pivotal juncture. The biotechnology leader posted a strong Q1 with 19% revenue growth and a non-GAAP EPS beat, yet shares have drifted lower amid concerns about the ongoing Eylea franchise transition and competitive pressures in the retinal disease market. This quarter's results will provide the first look at whether Eylea HD's unit demand momentum — which grew 10% sequentially in Q1 — can continue to offset the rapid erosion of legacy Eylea sales. Additionally, with the Sanofi development balance expected to be fully repaid by the end of Q2, Regeneron is poised to begin receiving its full share of collaboration profits starting in Q3, a milestone that many investors view as a potential inflection point for earnings.

Earnings Expectations

Wall Street consensus points to non-GAAP EPS in the range of $10.61 to $10.85 for Q2 2026, which would represent a year-over-year decline from the $12.89 reported in Q2 2025. Revenue is expected to land near $3.82 billion, compared with $3.68 billion in the prior-year quarter. On a GAAP basis, analysts forecast EPS of approximately $9.53.

Several factors are likely to influence the quarter's results. Management previously guided that the temporary manufacturing interruption at Regeneron's Limerick, Ireland facility would create a GAAP gross margin headwind in Q2, with full production expected to resume by quarter-end. Full-year GAAP gross margin is projected at 77% to 78%, compared with the 86% non-GAAP gross margin on net product sales reported in Q1. Separately, the company indicated a roughly $20 million negative impact to Eylea net sales from inventory absorption in Q2.

On the collaboration revenue front, investors will closely monitor Dupixent profit contributions and the trajectory of Libtayo, which delivered 54% global sales growth in Q1. The potential for an FDA decision on one or both Eylea HD pre-filled syringe applications also hangs over this quarter as a significant regulatory catalyst.

AI Screener

For investors seeking to identify opportunities beyond individual earnings reports, Tickeron's AI Screener offers a powerful, AI-driven stock and ETF discovery platform. The tool allows users to scan thousands of stocks and ETFs using customizable filters that span technical patterns, fundamental metrics, trend strength, volatility profiles, and proprietary AI-generated signals. Whether narrowing by industry, market capitalization, specific technical indicators, or price pattern recognition, the AI Screener helps traders and investors surface trade ideas, breakout candidates, and trending stocks far more efficiently than traditional manual screening methods. Exploring screening tools like this can complement earnings-season research by highlighting names that meet specific investment criteria across the broader market.

Market Reaction and Investor Sentiment

Market sentiment heading into the Q2 report appears cautious but not bearish. REGN shares are trading near $677, having recovered modestly from lows but still sitting well below the 52-week high of $821.11 and beneath the 200-day simple moving average of roughly $718. Analyst consensus stands at a "Moderate Buy," with 27 covering firms assigning 17 buy ratings, 9 holds, and 1 strong buy, alongside an average 12-month price target of approximately $788, suggesting meaningful upside from current levels.

Yet the stock's post-Q1 trajectory — a roughly 9% decline since the April 29 report — signals that investors remain wary. Key risk factors include the pace of Eylea HD conversion, competitive dynamics with Roche's Vabysmo, potential drug pricing policy developments following Regeneron's agreement with the U.S. government, and broader biotech sector sentiment. The Q2 report and accompanying commentary will need to address these concerns head-on to shift the narrative.

Forward Outlook and Key Factors to Monitor

Looking beyond the Q2 print, several interconnected themes will shape Regeneron's trajectory through the remainder of 2026 and into 2027.

First, the anticipated repayment of the Sanofi development balance by the end of Q2 means Regeneron should begin receiving its full share of collaboration profits starting in the third quarter. This mechanical shift in profit-sharing could provide a meaningful tailwind to earnings in the second half of the year and is arguably the single most important structural catalyst on the horizon.

Second, regulatory milestones are stacking up. A decision on the Eylea HD pre-filled syringe — which would enhance patient convenience and potentially support brand loyalty — could arrive at any time. Additionally, garetosmab faces an FDA decision date (PDUFA, or Prescription Drug User Fee Act action date) in August, while cemdisiran for paroxysmal nocturnal hemoglobinuria (PNH) is expected to report registrational results in late Q4, with an FDA decision also targeted for the fourth quarter.

Third, the commercial execution story revolves around Dupixent's continued label expansion — including recent approvals for chronic spontaneous urticaria (CSU) in younger children and allergic fungal rhinosinusitis — and whether Libtayo can sustain its impressive double-digit growth trajectory in the oncology market. These diversified revenue streams are increasingly important as the legacy Eylea franchise faces ongoing competitive and conversion-related headwinds.

Finally, cost management and capital allocation will remain in focus. With research and development (R&D) expenses rising 19% in Q1 to $1.4 billion to support a pipeline of nearly 50 clinical-stage candidates, and the board having authorized a new $3.0 billion share repurchase program in April, investors will assess whether Regeneron can balance aggressive internal investment with meaningful shareholder returns.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations